Facebook link Linked In link You Tube link

The Federation of Clinical Immunology Societies (FOCIS) exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases.

Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001 and we look forward to seeing you at our 17th Annual Meeting in Chicago, Illinois!  

Visit the FOCIS 2017 microsite to view the program, register, book a room and more!

News & Information

2017 Lupus Insight Prize Call for Nominations Underway

The Lupus Research Alliance is pleased to announce that the Lupus Insight Prize nominations are now underway. The Lupus Insight Prize recognizes a major, novel insight and/or discovery with the promise of changing thinking about lupus as well as a high likelihood of generating further advances in the diagnosis and treatment of the disease. Deadlines and nomination guidelines are available through the proposalCENTRAL website at https://proposalcentral.altum.com. Once there search for the Lupus Insight Prize.

The Lupus Insight Prize recipient will be awarded $150,000 to be used for research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment.

The full application must be submitted by the Nominator and the Candidate electronically by April 24, 2017 at 5 p.m. ET. All applications will be reviewed by members of an independent Selection Committee. Instructions on how to submit a nomination for the Lupus Insight Prize and the complete guidelines are available at www.LupusInsightPrize.org. The 2017 Prize will be awarded on June 15, 2017 at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting.

New Chilean Workshop Announced - FOCIS Goes South

We are glad to invite you to the first FOCIS course to be held in Santiago de Chile: "FOCIS goes South: Advances in Translational and Clinical Immunology" hosted by the Millennium Institute on Immunology and Immunotherapy (www.imii.cl), a recently incorporated FOCIS Excellence Center.

This workshop will be held this upcoming year 2017 on May 15-17th with excellent international and regional speakers.

The workshop will focus on immunological mechanisms and treatments in autoimmunity, cancer, inflammation and infectious diseases. This is a great opportunity for establishing and expanding collaborative networks in South America.

All Articles...

 

 FOCIS 2017 Sponsors

 Graphic of FOCIS 2017 Supporters

 

ePub header 2016

December 22, 2016
 
EDITOR: Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital  EDITORIAL BOARD: Abul K. Abbas, MD, University of California, San Francisco | Carla J. Greenbaum, MD, Benaroya Research Institute | Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital

Highlights from Recent Literature

circlearrow2 Early Dysregulation Leads to Autoimmune Disease in Adults
 

Antibodies against self-proteins can be present for years to decades before the development of overt autoimmune disease, suggesting that a loss of tolerance may exist amongst circulating immune cells that precedes tissue injury. The authors studied autoimmunity in a mouse model of Sjögren’s disease in order to identify the type and timing of immune dysregulation that made these mice susceptible to inflammatory disease later in life.

readmore

 
  Reviewed by Rachael A. Clark, MD, PhD, Brigham and Women's Hospital

 

Developments in Basic Immunology and Novel Therapies

circlearrow2 Exploiting Metabolism in T cells to Treat Immune Mediated Disease
 

Over the previous decade, several groups have elucidated details of metabolic pathways that drive survival, growth and differentiation in T lymphocytes1,2. T cells differ in their utilization of metabolic pathways and therefore energy sources depending on the specifics of T cell subset and state of activation. The bio-energetics needs of a resting naïve lymphocyte are different from one that is rapidly expanding and differentiating or actively regulating immune responses. It is now clear that this influences the quality and immune responses.

readmore

 
  Submitted by Jonathan S. Maltzman, MD, PhD, FAST, Veterans Affairs Palo Alto Health Care System and Stanford University

 

Selected Recent Clinical Trial Results

circlearrow2 Activity of Secukinumab, an Anti-IL-17A Antibody, on Brain Lesions in RRMS: Results From a Randomized, Proof-Of-Concept Study
 

Clinical Trial: Havrdova E, Belova A, Goloborodko A, et al. J Neurol (May 2016) 263:1287-1295

Disease: relapsing remitting multiple sclerosis (RRMS)

Intervention: secukinumab 10 mg/kg or placebo. Secukinumab is a human monoclonal antibody that binds to IL-17A

 

readmore

 
  Submitted by Sandra Lord, MD, Benaroya Research Institute. Edited by Carla J. Greenbaum, MD, Benaroya Research Institute


   

Share